Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 vaccine in Vaccinee in Saudi Arabia

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) had caused the current Coronavirus Disease 2019 (COVID-19) pandemic. The pandemic had resulted in a significant disruption of social live and had a major economic impact. Countries around the globe had taken extra-ordinary measures to combat the disease. The results from phase III clinical trials showed that both Pfizer-BioNTech messenger RNA (mRNA) vaccine (BNT162b2) and the Oxford-AstraZeneca adenovirus vector vaccine, ChAdOx1-S, also known as Ad26.COV2.S, vaccines very effective in decreasing disease and mortality with a planned two-dose schedule (Polack et al., 2020).

Source: International Journal of Infectious Diseases - July 25, 2021 Category: Infectious Diseases Authors: Salma AlBahrani, Ali AlBarraK, Othman Ali Alghamdi, Mesfer Abdullah alghamdi, Fatimah H. Hakami, Asmaa K. Al Abaadi, Sausan A. Alkhrashi, Mansour Y. Alghamdi, Meshael M. Almershad, Mansour Moklif Alenazi, Mohamed Hany ElGezery, Arulanantham Zechariah Jeba Source Type: research